Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18920477 | 0.87 | LMNA (0.56) | OPRM1OPRK1OPRL1OPRD1LMNA | |
| SCHEMBL14428555 | 0.84 | L3MBTL1 (0.53) | OPRM1OPRK1OPRL1OPRD1LMNA | |
| SCHEMBL628105 | 0.82 | LMNA (0.65) | OPRM1OPRK1OPRL1OPRD1LMNA | |
| SCHEMBL5184046 | 0.77 | ALDH1A1 (0.46) | LMNAPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL22095590 | 0.75 | ROCK2 (0.47) | OPRM1MEN1GFERKMT2AALDH1A1 | |
| SCHEMBL18920528 | 0.75 | LMNA (0.55) | LMNAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL18920486 | 0.75 | ALDH1A1 (0.62) | OPRM1OPRK1OPRL1LMNACHRNA1 | |
| SCHEMBL3234103 | 0.74 | L3MBTL1 (0.53) | LMNAL3MBTL1ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL13160613 | 0.74 | OPRM1 (0.50) | OPRM1OPRK1OPRL1OPRD1LMNA | |
| SCHEMBL18920471 | 0.73 | LMNA (0.52) | LMNASLC6A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| EP-1740553-A1 | ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS | AstraZeneca AB (SE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005100325-A1 | ARYL GLYCINAMIDE DERIVATIVES AND THEIR USE AS NK1 ANTAGONISTS AND SEROTONIN REUPTAKE INHIBITHORS | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | TPH1, NTSR1, HTR1D | OPRM1 143/4885OPRK1 89/4885OPRL1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.